We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Tests for Smell Loss May Detect Alzheimer’s and PD

By LabMedica International staff writers
Posted on 16 Oct 2017
In a new approach to testing for olfaction dysfunction, researchers have developed “white smells,” mixtures of several odor molecules, which help reduce test bias and patient subjectivity, thus also creating a more globally applicable testing format. More...
They suggest that these tests could also aid in earlier detection of neurological disorders that have been associated with olfaction problems.

The sense of smell is often taken for granted, until it malfunctions. Researchers at Rockefeller University (New York City, NY, USA) are developing a new type of test to help improve diagnosis of smell disorders and of associated diseases that can be detected with smell tests.

“People have their vision and hearing tested throughout their lives, but smell testing is exceedingly rare,” said Leslie Vosshall, who professor at Rockefeller U. and a Howard Hughes Medical Institute investigator, and who developed the new test format with Julien Hsieh, a Rockefeller clinical scholar who’s now a resident at the Geneva University Hospitals (Switzerland), and colleagues.

One problem with current tests for smell limitations is that they rely on a patient’s ability to detect and identify (name) single types of odor molecules, such as rose-scented phenylethyl alcohol. However, the ability to detect odors and to recognize them can vary greatly between people. Someone with an otherwise normal sense of smell may not be able to detect the rose molecule, while another person who can smell roses but is from an area where these flowers are scarce may struggle to put a name to the scent. In either case, there is the potential for misdiagnosis, particularly when testing across different populations and regions.

The researchers set out to eliminate these potential biases with the help of “white smells,” named based on conceptual similarity to “white light” as combination of wavelengths of light, and “white noise” as combination of many frequencies of sound. They prepared “white smells” by mixing many odors together to produce something unfamiliar, from assortments of 30 different odor molecules.

Their two new tests ask patients to distinguish white smells with overlapping ingredients and to detect white smells at increasingly lower concentrations. If a person is unable to detect a single component of the test scent, this has little effect on the result. Furthermore, test-takers do not need to identify the odor at all: “[The tests] focus on the problem of smell itself, because they don’t force people to match smells to words,” said Prof. Vosshall.

In clinical trials conducted at Rockefeller University Hospital (NY, USA) and Taichung Veterans General Hospital (Taiwan), the new tests detected smell loss more reliably than conventional options. The results open up the possibility of a better means to detect smell loss, and even to aid in detection of Alzheimer’s and Parkinson’s diseases by using “changes in the sense of smell, along with other biomarkers, to identify underlying causes of these neurological disorders very early, and so potentially improve treatment,” said Dr. Hsieh.

The study, by Hsieha JW et al, was published October 10, 2017, in the journal Proceedings of the National Academy of Sciences (PNAS).

Related Links:
Rockefeller University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.